Fate Therapeutics Lands $30,000,000 Series B Funding Round

  • Feed Type
  • Date
    11/16/2009
  • Company Name
    Fate Therapeutics
  • Mailing Address
    10931 North Torrey Pines Road La Jolla, CA 92037
  • Company Description
    The company’s revolutionary platform focuses on both regenerative and reprogramming medicine. Fate’s regenerative medicine platform involves developing drugs that awaken adult stem cells in the body to repair damaged cells and tissues. Fate’s reprogramming medicine platform involves developing drugs to reprogram mature adult cells into stem cells which when differentiated can become healthy heart, bone, brain or other tissues.
  • Website
    http://www.fatetherapeutics.com
  • Transaction Type
    Venture Equity
  • Transaction Amount
    $30,000,000
  • Transaction Round
    Series B
  • Proceeds Purposes
    The company is looking to complete enrollment in the initial clinical trial of FT-1050 by next spring.
  • M&A Terms
  • Venture Investor
    OVP Venture Partners
  • Venture Investor
    ARCH Venture Partners
  • Venture Investor
    Polaris Venture Partners
  • Venture Investor
    Venrock

By posting a comment, you agree to our terms and conditions.